NasdaqGM:EDAP - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	90	-8	N/A	N/A	2
12/31/2025	76	-13	N/A	N/A	4
12/31/2024	67	-18	N/A	N/A	4
3/31/2024	61	-18	-20	-16	N/A
12/31/2023	60	-21	-19	-15	N/A
9/30/2023	57	-21	-21	-17	N/A
6/30/2023	57	-17	-17	-13	N/A
3/31/2023	57	-11	-10	-7	N/A
12/31/2022	55	-3	-5	-3	N/A
9/30/2022	53	4	4	6	N/A
6/30/2022	51	3	3	5	N/A
3/31/2022	47	0	2	4	N/A
12/31/2021	44	1	3	4	N/A
9/30/2021	45	0	4	6	N/A
6/30/2021	45	0	N/A	N/A	N/A
3/31/2021	44	0	N/A	N/A	N/A
12/31/2020	42	-2	0	2	N/A
9/30/2020	38	-3	N/A	N/A	N/A
6/30/2020	39	-2	N/A	N/A	N/A
3/31/2020	42	0	N/A	N/A	N/A
12/31/2019	45	2	2	4	N/A
9/30/2019	46	4	N/A	N/A	N/A
6/30/2019	44	2	N/A	N/A	N/A
3/31/2019	40	0	N/A	N/A	N/A
12/31/2018	39	0	-2	0	N/A
9/30/2018	36	-1	N/A	N/A	N/A
6/30/2018	35	-1	-3	0	N/A
3/31/2018	36	-2	N/A	N/A	N/A
12/31/2017	36	-1	N/A	-3	N/A
9/30/2017	36	-2	N/A	N/A	N/A
6/30/2017	37	0	N/A	-4	N/A
3/31/2017	36	4	N/A	N/A	N/A
12/31/2016	36	4	N/A	1	N/A
9/30/2016	37	10	N/A	N/A	N/A
6/30/2016	35	4	N/A	4	N/A
3/31/2016	35	2	N/A	N/A	N/A
12/31/2015	32	-2	N/A	1	N/A
9/30/2015	27	-9	N/A	N/A	N/A
6/30/2015	27	2	N/A	-1	N/A
3/31/2015	25	-4	N/A	N/A	N/A
12/31/2014	26	-1	N/A	-1	N/A
9/30/2014	28	2	N/A	N/A	N/A
6/30/2014	27	-5	N/A	-1	N/A
3/31/2014	26	0	N/A	N/A	N/A
12/31/2013	24	-5	N/A	-2	N/A
9/30/2013	25	-6	N/A	N/A	N/A
6/30/2013	25	-6	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EDAP今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: EDAP今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: EDAP今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: EDAPの収益 ( 18.2% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: EDAPの収益 ( 18.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EDAPの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

EDAP TMS 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 35%, revenue upgraded

Consensus EPS estimates fall by 11%, revenue upgraded

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

Price target increased by 12% to US$14.50

Consensus EPS estimates increase by 36%

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 35%, revenue upgraded

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

Acceleration At EDAP

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Third quarter 2021 earnings released: €0.03 loss per share (vs €0.034 loss in 3Q 2020)

Price target decreased to US$11.50

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Mega Elektroniikka Oy agreed to acquire a 25% stake in Technomed Medical Systems S.A from EDAP TMS S.A. (NasdaqGM : EDAP).

Second quarter 2021 earnings released: €0.013 loss per share (vs €0.006 loss in 2Q 2020)